Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2013 Aug 17;3(8):e003199. doi: 10.1136/bmjopen-2013-003199

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/

PMC Copyright notice

Serum interleukin 6 (IL-6) concentration association with response to treatment. Forest plots show the effect and 95% CI for the association of IL-6 with cDAS28 at 16 weeks across treatment lines. cDAS28, change in DAS28 from baseline at week 16; CI; DMARD, disease-modifying antirheumatic drug; IR, inadequate responder; MTX, methotrexate; SD; TCZ, tocilizumab; TNF, tumour necrosis factor; , MTX/DMARD; , TCZ+MTX/DMARD.

Inline graphic — Serum interleukin 6 (IL-6) concentration association with response to treatment. Forest plots show the effect and 95% CI for the association of IL-6 with cDAS28 at 16 weeks across treatment lines. cDAS28, change in DAS28 from baseline at week 16; CI; DMARD, disease-modifying antirheumatic drug; IR, inadequate responder; MTX, methotrexate; SD; TCZ, tocilizumab; TNF, tumour necrosis factor; , MTX/DMARD; , TCZ+MTX/DMARD.